MARKET

TNXP

TNXP

Tonix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9800
-0.0600
-5.77%
After Hours: 0.9553 -0.0247 -2.52% 19:59 04/16 EDT
OPEN
1.000
PREV CLOSE
1.040
HIGH
1.010
LOW
0.9350
VOLUME
13.37M
TURNOVER
--
52 WEEK HIGH
2.460
52 WEEK LOW
0.5100
MARKET CAP
317.44M
P/E (TTM)
-1.2265
1D
5D
1M
3M
1Y
5Y
Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference
GlobeNewswire · 04/07 12:00
TNXP: Positive Efficacy Data for COVID-19 Vaccine in Non-Human Primates…
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update TNX-1800 Shows Efficacy in Non-Human Primates On March 17, 2021, Tonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) announced positive efficacy results for TNX-1800, the comp...
Zacks Small Cap Research · 04/07 09:49
BRIEF-Tonix Pharmaceuticals Holding Corp Files For Mixed Shelf Of Up To $500 Million
reuters.com · 04/01 22:56
8-K: Tonix Pharmaceuticals Holding Corp.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/27 04:04
Former Penny Stock PRQR Moving On Analyst Comment, Others Follow
Mar 25, 2021 (Penny Stocks via COMTEX) -- Shares of former penny stock ProQR Therapeutics (NASDAQ: PRQR) surged on Thursday morning. The company's stock...
Penny Stocks · 03/25 17:05
Insider Buys Tonix Pharmaceuticals Stock
 
Benzinga · 03/25 14:57
Radiation Injury Drugs Market Size, Growth, Trends, Demand, Segment Analysis and Forecasts 2020-2027 by Ameco Research
pune, India, Thu, 25 Mar 2021 03:06:16 / Comserve Inc. / -- Worldwide Radiation Injury Drugs Market 2020 Global Share, Growth and Forecast Analysis till...
Comserve · 03/25 07:08
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder
GlobeNewswire · 03/22 19:30
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TNXP. Analyze the recent business situations of Tonix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TNXP stock price target is 3.875 with a high estimate of 4.000 and a low estimate of 3.750.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 8.04M
% Owned: 2.48%
Shares Outstanding: 323.92M
TypeInstitutionsShares
Increased
10
3.17M
New
12
634.94K
Decreased
2
11.35K
Sold Out
9
429.80K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Chief Executive Officer/President/Director
Seth Lederman
Chief Financial Officer/Treasurer
Bradley Saenger
Chief Operating Officer
Jessica Morris
Executive Vice President
Herbert Harris
Secretary
Gregory Sullivan
Lead Director/Independent Director
James Treco
Director
Richard Bagger
Independent Director
Margaret Bell
Independent Director
Daniel Goodman
Independent Director
David Grange
Independent Director
Adeoye Olukotun
No Data
  • All
  • Financials
  • Insiders
More
About TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).

Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.